// AST – IMS - [DMinute_ROS]

Tronox LTD (TROX) Stock Declined While Fine Capital Partners LP Has Increased by $1.99 Million Its Stake; Great Point Partners Holding In Acceleron Pharma (XLRN) Was Has Boosted

Tronox Limited (NYSE:TROX) Logo

Great Point Partners Llc increased its stake in Acceleron Pharma Inc (XLRN) by 63.98% based on its latest 2018Q2 regulatory filing with the SEC. Great Point Partners Llc bought 295,755 shares as the company’s stock rose 39.12% with the market. The hedge fund held 758,000 shares of the biological products (no diagnostic substances) company at the end of 2018Q2, valued at $36.78 million, up from 462,245 at the end of the previous reported quarter. Great Point Partners Llc who had been investing in Acceleron Pharma Inc for a number of months, seems to be bullish on the $2.26 billion market cap company. The stock decreased 9.12% or $4.91 during the last trading session, reaching $48.94. About 575,321 shares traded or 46.94% up from the average. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 31.27% since December 5, 2017 and is uptrending. It has outperformed by 15.65% the S&P500. Some Historical XLRN News: 02/05/2018 – Acceleron Presenting at UBS Conference May 22; 22/03/2018 – CAFC: DELL INC. v. ACCELERON, LLC [ERRATA] – Appeal #17-1101 – 2018-03-22; 26/04/2018 – Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting; 01/05/2018 – ACCELERON GETS FDA FAST TRACK FOR ACE-083 IN FSHD; 08/05/2018 – ACCELERON 1Q LOSS/SHR 58C, EST. LOSS/SHR 65C; 22/05/2018 – Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension; 08/05/2018 – ACCELERON PHARMA – BELIEVES EXISTING CASH, CASH EQUIVALENTS & INVESTMENTS TO BE SUFFICIENT TO FUND PROJECTED OPERATING REQUIREMENTS INTO 2021; 01/05/2018 – Acceleron Receives FDA Fast Track Designation For ACE-083 In Facioscapulohumeral Muscular Dystrophy (FSHD); 08/05/2018 – Acceleron Pharma 1Q Loss/Shr 58c; 21/05/2018 – Acceleron Presenting at UBS Conference Tomorrow

Fine Capital Partners Lp increased its stake in Tronox Ltd (TROX) by 6.55% based on its latest 2018Q2 regulatory filing with the SEC. Fine Capital Partners Lp bought 104,804 shares as the company’s stock declined 32.33% while stock markets rallied. The hedge fund held 1.71M shares of the major chemicals company at the end of 2018Q2, valued at $33.57 million, up from 1.60M at the end of the previous reported quarter. Fine Capital Partners Lp who had been investing in Tronox Ltd for a number of months, seems to be bullish on the $1.23 billion market cap company. The stock decreased 8.33% or $0.91 during the last trading session, reaching $10.01. About 993,837 shares traded. Tronox Limited (NYSE:TROX) has declined 42.00% since December 5, 2017 and is downtrending. It has underperformed by 57.62% the S&P500. Some Historical TROX News: 21/03/2018 – Tronox Enters into Purchase Agreement to Sell Electrolytic Operations; 09/05/2018 – TRONOX LTD TROX.N – IN UNITED STATES, FILED A MOTION WITH FTC SEEKING TO STAY ADMINISTRATIVE PROCEEDING SCHEDULED TO START ON MAY 18; 09/05/2018 – TRONOX LTD – OBTAINING EC’S CONDITIONAL CLEARANCE OF CRISTAL NOW ONLY DEPENDENT ON FINALIZING AGREEMENT ON REMEDY TO ADDRESS REMAINING OBJECTION; 21/03/2018 – TRONOX – UNIT HAS ENTERED INTO PURCHASE AGREEMENT WITH EMD ACQUISITION LLC TO SELL CERTAIN ASSETS AND LIABILITIES OF ITS ELECTROLYTIC OPERATIONS; 21/03/2018 – TRONOX SEES $25M-$30M PRETAX IMPAIRMENT ON ASSET SALE; 25/04/2018 – EXXARO RESOURCES – INTENTION TO SEEK SHAREHOLDER APPROVAL TO FURTHER MONETISE ITS REMAINING STAKE IN TRONOX LTD IN ORDER TO FOCUS ON CORE ACTIVITIES; 07/03/2018 – TRONOX SAYS FTC SUIT NO LONGER WARRANTED, VOLUNTARILY DISMISSED; 25/04/2018 – EXXARO CURRENTLY HOLDS SHRS WORTH ABOUT $476M IN TRONOX; 07/03/2018 – TRONOX WORKING WITH U.S, EUROPE TO FIND RESOLUTION TO CONCERNS; 09/05/2018 – Tronox 1Q Loss/Shr 36c

More notable recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: Nasdaq.com which released: “Celgene (CELG) Announces Various Cancer Data at ASH 2018 – Nasdaq” on December 03, 2018, also Streetinsider.com with their article: “Celgene (CELG), Acceleron (XLRN) Report Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III BELIEVE Study in Adults with Transfusion-Dependent Beta-Thalassemia – StreetInsider.com” published on July 09, 2018, Seekingalpha.com published: “Acceleron: Luspatercept New Data Is A Buy Signal – Seeking Alpha” on June 07, 2018. More interesting news about Acceleron Pharma Inc. (NASDAQ:XLRN) were released by: Seekingalpha.com and their article: “Acceleron Pharma: Updates To Thesis – Seeking Alpha” published on January 15, 2018 as well as Seekingalpha.com‘s news article titled: “Acceleron Pharma’s (XLRN) CEO Habib Dable on Q1 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: May 14, 2018.

Since June 29, 2018, it had 0 insider buys, and 2 insider sales for $1.88 million activity.

Investors sentiment increased to 1.47 in 2018 Q2. Its up 0.20, from 1.27 in 2018Q1. It is positive, as 17 investors sold XLRN shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 38.98 million shares or 1.76% more from 38.30 million shares in 2018Q1 were reported. Eagle Asset Mgmt reported 888,411 shares stake. Fmr Ltd Liability Co reported 4.41M shares. Wells Fargo & Com Mn accumulated 0% or 36,001 shares. Captrust Financial Advisors, a North Carolina-based fund reported 3 shares. Geode Capital Management Ltd Liability reported 399,975 shares stake. Moreover, Great West Life Assurance Can has 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 5,080 shares. Credit Suisse Ag owns 40,504 shares. Loring Wolcott And Coolidge Fiduciary Limited Liability Partnership Ma invested in 337 shares or 0% of the stock. Sectoral Asset Mngmt accumulated 1.66% or 306,626 shares. Artal Gru reported 1.00 million shares or 1.03% of all its holdings. Schwab Charles Management Incorporated invested in 0.01% or 205,240 shares. United Svcs Automobile Association owns 73,493 shares or 0.04% of their US portfolio. Legal And General Grp Pcl reported 13,565 shares. Brown Advisory Inc stated it has 512,206 shares. Highland Management LP owns 6,000 shares or 0.02% of their US portfolio.

Great Point Partners Llc, which manages about $935.83 million and $721.56 million US Long portfolio, decreased its stake in Cti Biopharma Corp by 150,000 shares to 1.54M shares, valued at $7.65 million in 2018Q2, according to the filing. It also reduced its holding in Novocure Ltd by 39,483 shares in the quarter, leaving it with 713,998 shares, and cut its stake in Acceleron Pharma Inc (Call) (NASDAQ:XLRN).

Among 17 analysts covering Acceleron Pharma (NASDAQ:XLRN), 12 have Buy rating, 0 Sell and 5 Hold. Therefore 71% are positive. Acceleron Pharma had 47 analyst reports since August 13, 2015 according to SRatingsIntel. On Tuesday, August 1 the stock rating was maintained by Oppenheimer with “Hold”. The firm has “Outperform” rating by Credit Suisse given on Thursday, January 21. The stock has “Overweight” rating by Barclays Capital on Wednesday, April 27. Credit Suisse maintained it with “Outperform” rating and $51 target in Tuesday, November 14 report. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) earned “Hold” rating by Oppenheimer on Tuesday, May 22. The company was initiated on Tuesday, December 13 by Oppenheimer. The company was upgraded on Tuesday, September 18 by PiperJaffray. On Monday, June 13 the stock rating was maintained by Barclays Capital with “Overweight”. The rating was maintained by H.C. Wainwright on Wednesday, February 28 with “Buy”. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) has “Equal-Weight” rating given on Friday, July 13 by Morgan Stanley.

Since August 13, 2018, it had 0 insider purchases, and 1 sale for $156,600 activity.

More notable recent Tronox Limited (NYSE:TROX) news were published by: Seekingalpha.com which released: “Stocks To Watch: Favorable Trade Winds? – Seeking Alpha” on December 01, 2018, also Seekingalpha.com with their article: “Tronox acquisition of Cristal’s titanium dioxide business blocked by U.S. court – Seeking Alpha” published on September 05, 2018, Nasdaq.com published: “Mid-Day Market Update: Foot Locker Gains On Upbeat Earnings; Heat Biologics Shares Plummet – Nasdaq” on November 21, 2018. More interesting news about Tronox Limited (NYSE:TROX) were released by: Nasdaq.com and their article: “Mid-Afternoon Market Update: On Deck Capital Jumps On Earnings Beat; Invacare Shares Plummet – Nasdaq” published on November 06, 2018 as well as Streetinsider.com‘s news article titled: “Tronox (TROX) Seeks Permission to Present Proposed Divestiture of Ashtabula Complex to FTC Commissioners as Remedy for its Pending Cristal Acquisition – StreetInsider.com” with publication date: December 04, 2018.

Investors sentiment increased to 1.15 in Q2 2018. Its up 0.21, from 0.94 in 2018Q1. It increased, as 21 investors sold TROX shares while 45 reduced holdings. 25 funds opened positions while 51 raised stakes. 84.31 million shares or 4.13% more from 80.97 million shares in 2018Q1 were reported. Credit Suisse Ag reported 75,050 shares stake. Neuberger Berman Gru Llc has 266,901 shares. Captrust Financial has invested 0% of its portfolio in Tronox Limited (NYSE:TROX). Bluecrest Cap Mgmt Ltd has 60,000 shares for 0.03% of their portfolio. Bancorporation Of Montreal Can has 1,137 shares for 0% of their portfolio. Kepos Cap Limited Partnership owns 650,000 shares. California Employees Retirement Sys, California-based fund reported 122,052 shares. Creative Planning owns 156,489 shares. Fmr Llc holds 13.80 million shares. Nomura Hldg Incorporated holds 0% or 29,500 shares. Kennedy Capital Management holds 420,286 shares or 0.15% of its portfolio. Pnc Services Group Incorporated owns 106 shares or 0% of their US portfolio. Capital Growth Mgmt Lp has 20,000 shares. Schwab Charles owns 778,924 shares or 0.01% of their US portfolio. Citigroup Inc reported 62,397 shares.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.